A world-first personalised cancer vaccine developed by Australian researchers, led by Professor Georgina Long, has successfully passed its phase three trial for melanoma treatment. The mRNA vaccine works by analysing a patient's removed tumour and blood to create a personalised treatment that teaches the immune system to identify and fight cancer cells if they return, administered alongside the immunotherapy drug Keytruda. This marks the first mRNA cancer treatment to succeed in a phase three trial, with full results to be unveiled in Madrid in October as researchers expand testing to other cancers.
See omnystudio.com/listener for privacy information.